Description
The study shows that sEV from diabetic, obese, and ischemic patients have different angiogenic capabilities, but the underlying mechanisms driving these population-specific differences remain unexplained. Understanding these mechanisms is critical for developing personalized sEV-based therapies.
Gap type: unexplained_observation Source paper: miR-130a and Tgfβ Content in Extracellular Vesicles Derived from the Serum of Subjects at High Cardiovascular Risk Predicts their In-Vivo Angiogenic Potential. (2020, Scientific reports, PMID:31959759)